文献速递胸部肿瘤

奥希替尼用于EGFR TKI一线治疗后进展的EGFR突变阳性NSCLC的成本效果

Cost-Effectiveness of Osimertinib for EGFR Mutation-Positive Non-Small Cell Lung Cancer after Progression following First-Line EGFR TKI Therapy.
PubMed 文献 · J Thorac Oncol · 2017-10-31

该研究通过决策树与马尔可夫模型,评估奥希替尼对比标准化疗用于EGFR T790M突变且一线EGFR TKI治疗进展后晚期NSCLC的成本效果。从美国支付方和中国卫生体系视角,奥希替尼的ICER分别为每QALY 232,895美元和48,081美元(整体人群),均超过意愿支付阈值。结论认为奥希替尼不太可能具有成本效果,除非降价。

要点

  • 奥希替尼用于T790M突变NSCLC,美国和中国视角的ICER均超过意愿支付阈值。
  • 奥希替尼价格是影响成本效果的最主要参数。
  • 若奥希替尼降价,经济性可能转为有利。

核心结论

  • 从美国和中国视角,奥希替尼治疗T790M突变NSCLC不太可能具有成本效果。
  • 若奥希替尼价格降低,经济结果可能变得有利。

研究设计与样本

  • 采用决策树与马尔可夫模型,评估奥希替尼对比标准化疗的成本效果。
  • 数据来自随机临床试验和已发表报告,成本从美国支付方和中国卫生体系视角估算。
  • 所有成本和ICER以2017年美元呈现,并进行敏感性和场景分析(三种T790M检测设置)。

主要发现

  • 美国整体人群:血浆和组织分子检测后奥希替尼较化疗增加0.359 QALY,增量成本83,515美元/人,ICER 232,895美元/QALY。
  • 美国中枢神经系统转移且EGFR T790M突变人群:增加0.313 QALY,增量成本74,924美元/人,ICER 239,274美元/QALY。
  • 中国整体人群ICER为48,081美元/QALY,中国中枢神经系统转移人群ICER为53,244美元/QALY。
  • 已知T790M突变者,奥希替尼较化疗的ICER也超过意愿支付阈值。
  • 奥希替尼价格是最具影响力的参数。

临床怎么用

  • 在决策奥希替尼用于T790M突变NSCLC时,需考虑其较高的经济负担。
  • 奥希替尼降价可能改善其成本效果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The aim of this study was to investigate the cost-effectiveness of osimertinib for the treatment of advanced NSCLC with an EGFR T790M mutation after the failure of first-line EGFR tyrosine kinase inhibitor (TKI) therapy. METHODS: A mathematical model was established by combining a decision tree and the Markov approach to project the cost-effectiveness of osimertinib versus standard chemotherapy for the treatment of patients who harbor an EGFR T790M mutation and have disease progression after first-line EGFR TKI therapy with or without metastases to the central nervous system. The clinical and outcome data were derived from randomized clinical trials and published reports. The health outcome data included quality-adjusted life-years (QALY). The cost data were estimated from the perspectives of the payer in the United States and the health care system in the People's Republic of China. All costs and incremental cost-effectiveness ratios (ICERs) were presented in 2017 U.S. dollars. Sensitivity and scenario analyses with three different settings of T790M mutation testing were performed. RESULTS: Compared with chemotherapy, molecular testing in plasma and tissue followed by osimertinib treatment yielded an additional 0.359 and 0.313 QALYs in the entire U.S. population and the population of those with central nervous system metastases and an EGFR T790M mutation. For these populations, the incremental costs were $83,515 and $74,924 per patient, respectively, and the ICERs were $232,895 and $239,274 per QALY, respectively. For the entire Chinese population and the Chinese population with central nervous system metastases, the ICERs were $48,081 and $53,244 per QALY, respectively. For those with a known T790M mutation, the ICERs of osimertinib over chemotherapy also exceeded the willingness-to-pay threshold. The most influential parameter was the price of osimertinib. CONCLUSION: Osimertinib treatment for T790M mutation NSCLC is unlikely to be cost-effective from the perspectives of the United States and the People's Republic of China. If the price of osimertinib could be decreased, the economic outcome might become favorable.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Wu B, Gu X, Zhang Q, et al. Cost-Effectiveness of Osimertinib for EGFR Mutation-Positive Non-Small Cell Lung Cancer after Progression following First-Line EGFR TKI Therapy. J Thorac Oncol. 2017. PMID: 29101057. doi:10.1016/j.jtho.2017.10.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。